Supernus Pharmaceuticals, Inc.
SUPN
Κατάταξη σε μετοχές
#5607
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Τιμή μετοχής
$41.34
Κεφαλαιοποίηση
$2.41B
Αλλαγή (1 ημέρα)
3.75%
Αλλαγή (1 έτος)
-19.39%
Χώρα
US
Εμπόριο Supernus Pharmaceuticals, Inc. (SUPN)
Κατηγορία
Healthcare
Δείκτης P/S για Supernus Pharmaceuticals, Inc. (SUPN)
Δείκτης P/S στις 2026 TTM: 0
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Supernus Pharmaceuticals, Inc., ο τρέχων δείκτης P/S (TTM) είναι 0. Στο τέλος του 2026, ο δείκτης ήταν 0.
Ιστορικό P/S για την Supernus Pharmaceuticals, Inc. από 2026 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες. | ||
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | - |
IN
|
